## Tuong M Ho

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8870109/publications.pdf

Version: 2024-02-01

430874 377865 1,281 49 18 34 h-index citations g-index papers 50 50 50 877 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Intracytoplasmic sperm injection for all or for a few?. Fertility and Sterility, 2022, 117, 270-284.	1.0	4
2	Development of children born from IVM versus IVF: 2-year follow-up of a randomized controlled trial. Human Reproduction, 2022, 37, 1871-1879.	0.9	10
3	Effect of postâ€warming culture time on the live birth rate after frozen embryo transfer. Reproductive Medicine and Biology, 2022, 21, .	2.4	2
4	Healthy Genetically Normal Live-Birth After Mosaic Chromosome 5 Embryo Transfer: A Case Report. Fertility & Reproduction, 2021, 03, 19-24.	0.1	0
5	Low Prognosis by the POSEIDON Criteria in Women Undergoing Assisted Reproductive Technology: A Multicenter and Multinational Prevalence Study of Over 13,000 Patients. Frontiers in Endocrinology, 2021, 12, 630550.	3.5	12
6	Micronized progesterone plus dydrogesterone versus micronized progesterone alone for luteal phase support in frozen-thawed cycles (MIDRONE): a prospective cohort study. Human Reproduction, 2021, 36, 1821-1831.	0.9	32
7	The effect of polymorphisms in <i>FSHR</i> and <i>FSHB</i> genes on ovarian response: a prospective multicenter multinational study in Europe and Asia. Human Reproduction, 2021, 36, 1711-1721.	0.9	21
8	Fresh embryo transfer versus freeze-only after in vitro maturation with a pre-maturation step in women with high antral follicle count: a randomized controlled pilot study. Journal of Assisted Reproduction and Genetics, 2021, 38, 1293-1302.	2.5	13
9	Antral follicle count and anti-M $\tilde{A}^{1}$ /allerian hormone to classify low-prognosis women under the POSEIDON criteria: a classification agreement study of over 9000 patients. Human Reproduction, 2021, 36, 1530-1541.	0.9	16
10	Intracytoplasmic sperm injection versus conventional in-vitro fertilisation in couples with infertility in whom the male partner has normal total sperm count and motility: an open-label, randomised controlled trial. Lancet, The, 2021, 397, 1554-1563.	13.7	56
11	Cumulative delivery rate per aspiration IVF/ICSI cycle in POSEIDON patients: a real-world evidence study of 9073 patients. Human Reproduction, 2021, 36, 2157-2169.	0.9	30
12	Perspectives on the development and future of oocyte IVM in clinical practice. Journal of Assisted Reproduction and Genetics, 2021, 38, 1265-1280.	2.5	82
13	COVID-19 Pandemic Impacts Decision-Making and Psychosocial Behavior in Women Seeking Fertility Treatment in APAC—an ASPIRE Patient Experience Report. Fertility & Reproduction, 2021, 03, 58-77.	0.1	1
14	Positive effects of amphiregulin on human oocyte maturation and its molecular drivers in patients with polycystic ovary syndrome. Human Reproduction, 2021, 37, 30-43.	0.9	15
15	Blastocyst Prediction of Day-3 Cleavage-Stage Embryos Using Machine Learning. Fertility & Reproduction, 2021, 03, 150-155.	0.1	1
16	Live birth after in vitro maturation in women with gonadotropin resistance ovary syndrome: report of two cases. Journal of Assisted Reproduction and Genetics, 2021, 38, 3243-3249.	2.5	6
17	Live births after oocyte in vitro maturation with a prematuration step in women with polycystic ovary syndrome. Journal of Assisted Reproduction and Genetics, 2020, 37, 347-357.	2.5	66
18	The effect of intra-ovarian androgen priming on ovarian reserve parameters in Bologna poor responders. Reproductive BioMedicine Online, 2020, 40, 223-228.	2.4	6

#	Article	IF	CITATIONS
19	Endocrine Requirements for Oocyte Maturation Following hCG, GnRH Agonist, and Kisspeptin During IVF Treatment. Frontiers in Endocrinology, 2020, 11, 537205.	3.5	18
20	In-vitro maturation of oocytes versus conventional IVF in women with infertility and a high antral follicle count: a randomized non-inferiority controlled trial. Human Reproduction, 2020, 35, 2537-2547.	0.9	62
21	Development of children born from freeze-only versus fresh embryo transfer: follow-up of a randomized controlled trial. Fertility and Sterility, 2020, 114, 558-566.	1.0	14
22	The early luteal hormonal profile in IVF patients triggered with hCG. Human Reproduction, 2020, 35, 157-166.	0.9	33
23	Determinants of the hCG Concentration in the Early Luteal Phase After Final Maturation of Follicles With Bolus Trigger of Recombinant hCG. Frontiers in Endocrinology, 2020, 11, 137.	3.5	9
24	Corifollitropin alfa versus follitropin beta: an economic analysis alongside a randomized controlled trial in women undergoing IVF/ICSI. Reproductive Biomedicine and Society Online, 2020, 10, 28-36.	1.8	3
25	SARS-CoV-2 and Assisted Reproductive Technology Practice: An Asia Pacific Initiative on Reproduction (ASPIRE) Position Paper. Fertility & Reproduction, 2020, 02, 115-143.	0.1	2
26	Use of Corifollitropin Alfa for Ovarian Stimulation: A Retrospective Analysis of 804 Women Undergoing IVF/ICSI. Fertility & Reproduction, 2019, 01, 93-98.	0.1	0
27	Biphasic in vitro maturation (CAPA-IVM) specifically improves the developmental capacity of oocytes from small antral follicles. Journal of Assisted Reproduction and Genetics, 2019, 36, 2135-2144.	2.5	72
28	In vitro maturation (IVM) versus in vitro fertilization (IVF) in women with high antral follicle count (AFC): a randomized controlled trial (NCT03405701). Fertility and Sterility, 2019, 112, e435-e436.	1.0	2
29	Live birth rates with a freeze-only strategy versus fresh embryo transfer: secondary analysis of a randomized clinical trial. Reproductive BioMedicine Online, 2019, 38, 387-396.	2.4	17
30	Gonadotropin-Releasing Hormone Agonist Versus Human Chorionic Gonadotropin for Ovulation Induction in Polycystic Ovary Syndrome Patients Undergoing Intrauterine Insemination: A Randomised Controlled Trial. Fertility & Reproduction, 2019, 01, 88-92.	0.1	0
31	The effectiveness of ICSI versus conventional IVF in couples with non-male factor infertility: study protocol for a randomised controlled trial. Human Reproduction Open, 2019, 2019, hoz006.	5.4	12
32	The Place of In Vitro Maturation in Assisted Reproductive Technology. Fertility & Reproduction, 2019, 01, 11-15.	0.1	19
33	Live Birth Rate After Transfer of Fresh or Frozen Poor Quality Day-3 Embryos Only. Fertility & Reproduction, 2019, 01, 161-168.	0.1	1
34	The prevalence of job stressors among nurses in private in vitro fertilization (IVF) centres. Nursing Open, 2019, 6, 39-49.	2.4	4
35	IVF Transfer of Fresh or Frozen Embryos in Women without Polycystic Ovaries. New England Journal of Medicine, 2018, 378, 137-147.	27.0	173
36	IVF Transfer of Fresh or Frozen Embryos in Women Without Polycystic Ovaries. Obstetrical and Gynecological Survey, 2018, 73, 214-215.	0.4	1

#	Article	IF	CITATIONS
37	Effectiveness and safety of in vitro maturation of oocytes versus in vitro fertilisation in women with high antral follicle count: study protocol for a randomised controlled trial. BMJ Open, 2018, 8, e023413.	1.9	21
38	Follicle Size on Day of Trigger Most Likely to Yield a Mature Oocyte. Frontiers in Endocrinology, 2018, 9, 193.	<b>3.</b> 5	78
39	A cost-effectiveness analysis of freeze-only or fresh embryo transfer in IVF of non-PCOS women. Human Reproduction, 2018, 33, 1907-1914.	0.9	34
40	Effect of GnRHa ovulation trigger dose on follicular fluid characteristics and granulosa cell gene expression profiles. Journal of Assisted Reproduction and Genetics, 2017, 34, 471-478.	2.5	5
41	Corifollitropin alfa followed by highly purified HMG versus recombinant FSH in young poor ovarian responders: a multicentre randomized controlled clinical trial. Human Reproduction, 2017, 32, 2225-2233.	0.9	34
42	Corifollitropin alfa vs recombinant FSH for controlled ovarian stimulation in women aged 35–42 years with a body weight ≥50 kg: a randomized controlled trial. Human Reproduction Open, 2017, 2017, hox023.	5 <b>.</b> 4	5
43	Gonadotropin-releasing hormoneÂagonist trigger in oocyteÂdonors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study. Fertility and Sterility, 2016, 105, 356-363.	1.0	52
44	Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged >=35 years: a randomized controlled trial. Human Reproduction, 2015, 30, 1188-1195.	0.9	44
45	A randomized double blind comparison of atosiban in patients undergoing IVF treatment. Human Reproduction, 2014, 29, 2687-2694.	0.9	48
46	Anti-MÃ $\frac{1}{4}$ llerian hormone versus antral follicle count for defining the starting dose of FSH. Reproductive BioMedicine Online, 2013, 27, 390-399.	2.4	59
47	Atosiban improves implantation and pregnancy rates in patients with repeated implantation failure. Reproductive BioMedicine Online, 2012, 25, 254-260.	2.4	54
48	Ovulation induction using low-dose step-up rFSH in Vietnamese women with polycystic ovary syndrome. Reproductive BioMedicine Online, 2009, 18, 516-521.	2.4	13
49	Progesterone supplementation during cryopreserved embryo transfer cycles: efficacy and convenience of two vaginal formulations. Reproductive BioMedicine Online, 2008, 17, 318-323.	2.4	19